Halozyme Therapeutics Inc $ 15.36 0 (0%)
On watch
Volume:
845,186
Avg Vol (1m):
761,501
Market Cap $:
2.25 Bil
Enterprise Value $:
2.05 Bil
P/E (TTM):
0.00
P/B:
8.60
| Earnings Power Value | ||
| Net Current Asset Value | ||
| Tangible Book | ||
| Projected FCF | ||
| Median P/S Value | ||
|
Price: $15.36 | ||
Manual of Stocks™ Web
Financial Strength | 6/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 3.14 | ||
| Equity-to-Asset | 0.62 | ||
| Debt-to-Equity | 0.35 | ||
| Debt-to-EBITDA | -3.61 | ||
| Piotroski F-Score | 2 | ||
| Altman Z-Score | 7.61 | ||
| Beneish M-Score | -2.19 | ||
| WACC vs ROIC | |||
Profitability | 3/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -20.1 | ||
| Net Margin % | -23.53 | ||
| ROE % | -16.94 | ||
| ROA % | -9.7 | ||
| ROC (Joel Greenblatt) % | -86.74 | ||
| 3-Year Revenue Growth Rate | -0.3 | ||
| 3-Year EBITDA Growth Rate | -27.3 | ||
| 3-Year EPS without NRI Growth Rate | -30.8 |
Ratios |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Forward PE Ratio | 30.67 | ||
| PB Ratio | 8.6 | ||
| PS Ratio | 12.29 | ||
| EV-to-EBIT | -71.72 | ||
| EV-to-EBITDA | -80.86 | ||
| EV-to-Revenue | 11.28 | ||
| Current Ratio | 2.89 | ||
| Quick Ratio | 2.57 | ||
| Days Inventory | 711.23 | ||
| Days Sales Outstanding | 64.66 | ||
| Days Payable | 356.23 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.1 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 8.58 | ||
| Price-to-Median-PS-Value | 0.7 | ||
| Earnings Yield (Greenblatt) % | -1.4 |